Design and Rationale of the FICAPP Study: Frailty in Cardiac Amyloidosis: Profiling the Phenotype

Heart Lung and Circulation 2026 Open access

Read full text
Authors: E. E. MONTGOMERY, Natasha Gorrie, GEORGIA MCCAUGHAN, Antonia S. Carroll, Kris Rogers, Karan Shahi, Julee McDonagh, Peter S. Macdonald, N. Bart
DOI: 10.1016/j.hlc.2026.03.054
Cited by: 1
References: 32

Abstract

BACKGROUND & AIM: Cardiac amyloidosis is an infiltrative cardiomyopathy associated with significant morbidity and mortality. Frailty, a biologic syndrome of decreased physiologic reserve, may be common and clinically significant in this population, yet remains insufficiently characterised. We aim to determine the prevalence and characteristics of frailty among adults with cardiac amyloidosis, and examine its association with functional status, quality of life, and disease severity. METHODS & DESIGN: As a prospective, observational, single-centre cohort study, adults with confirmed cardiac amyloidosis will undergo standardised frailty assessment. The prevalence of physical frailty (≥3 criteria) and cognitive frailty (≥2 frailty criteria plus mild cognitive impairment (MoCA

Fields of Study & Subjects

Amyloidosis: Diagnosis Treatment Outcomes Parathyroid Disorders and Treatments Alzheimer's disease research and treatments

Publication details

Journal / source
Heart Lung and Circulation
Publisher
Elsevier BV
Volume
35
Issue
6
Pages
778–786
Publication date
12 May 2026
Language
EN